📰 ReutersReutersCodex · 实盘不做把握 5/10
北京时间·🕒 发布 07-31 04:20:56时区推断·⟳ 抓取 07-31 04:21:16·⚡ 决策 08-01 06:55:39 +1d02h·87.6 天前
美国二巡法院恢复部分口服苯肾上腺素“最大强度”虚假广告诉讼
本次是诉讼程序性逆转，方向上对相关药企和零售商偏负面，但法院同时认定多数州法索赔被FDCA预先排除，并驳回RICO站位，负面范围被明显收窄。
📄 原文Reuters↗ 原文
A federal appeals court on Thursday revived portions of nationwide litigation in which consumers accused drugmakers su…
不做 Perrigo（PRGO.US）
利空方向成立但不是强空催化：PE诉讼和上诉已在公司披露中存在，本次只恢复部分索赔且未量化赔偿，做空红线不足。
不做 Haleon（HLN.US）
Advil相关敞口直接但本次裁定范围有限，核心PE无效监管风险已在2023-2024年公开，缺少短线可量化损害。
不做 宝洁（PG.US）
Vicks产品被点名但相对宝洁整体市值和收入过小，且多数索赔被预先排除，不足以做空超大市值消费品公司。
不做 CVS Health（CVS.US）
零售商标签诉讼为直接利空但金额和责任边界未定，且对CVS整体业务影响难以达到短线重定价强度。
不做 Kenvue（KVUE.US）
被告身份带来法律尾部风险，但本次没有新增赔偿金额、禁售最终令或产品线收入量级，当前不建立空单。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- FDA说明顾问委员会已在2023年9月会议中一致认为现有科学数据不支持口服PE推荐剂量作为鼻减充血剂有效，底层功效争议早已公开。
- EDNY此前整体驳回PE MDL bellwether complaint，认为相关索赔主要被联邦法预先排除，这是本次二审恢复部分索赔的前置程序背景。
- FDA正式提议将口服PE从OTC鼻减充血剂专论中移除，但强调只有最终命令才会影响产品销售，监管层面风险已提前进入市场视野。
- Reuters报道二巡恢复“maximum strength”标签索赔及部分NDA品牌药标签索赔，但多数州法索赔和民事RICO索赔仍被驳回。市场反应:行情工具HTTP 504，未能可靠取得事件后价格反应。
关键理由
- 本次是诉讼程序性逆转，方向上对相关药企和零售商偏负面，但法院同时认定多数州法索赔被FDCA预先排除，并驳回RICO站位，负面范围被明显收窄。
- 口服苯肾上腺素疗效问题并非新信息：FDA顾问委员会2023年已认定推荐剂量证据不支持疗效，FDA 2024年11月已提议从OTC专论中移除该成分。
- 对PG、CVS、Haleon、Kenvue等大市值/多业务公司，当前只恢复部分标签索赔，未给出赔偿金额、和解框架或产品收入占比，短线做空强度不够。
主要风险
- 若后续集体诉讼认证、赔偿口径或和解金额显著扩大，PRGO.US、HLN.US等OTC敞口较高公司可能需要重新评估空头或风险信号。
- 行情与内部KB工具本轮多次HTTP 504，未能用真实价量确认事件后市场反应；但不做结论主要基于催化强度和旧闻属性，而非无法取价。
反向证据
- 做空前查反向 · 来源 web · 日期 2026-07-30 · 影响 weakens
Reuters称二巡只恢复部分标签和NDA品牌药相关索赔，同时维持多数州法索赔预先排除并认定消费者缺乏RICO站位，削弱做空强度。
检索:court revived phenylephrine maximum strength claims but dismissed most claims RICO preemption 原文 ↗ - 做空前查反向 · 来源 web · 日期 2024-11-07 · 影响 weakens
FDA说明当前只是拟议命令，只有最终命令才影响可销售产品，且会给予改革配方或下架时间，降低突发经营损害。
检索:FDA oral phenylephrine proposed order final order products may continue marketed 原文 ↗ - 做空前查反向 · 来源 web · 日期 2025-02-28 · 影响 weakens
Perrigo披露无法可靠估计潜在财务影响，相关事项属于既有MDL和上诉风险；未见本次裁定带来可量化新增损失。
检索:Perrigo phenylephrine lawsuits maximum strength revenue exposure decongestant 原文 ↗ - 做空前查反向 · 来源 kb_search · 影响 none
内部KB检索实际调用但服务HTTP 504，未能补充内部付费源旧闻或反证。
检索:oral phenylephrine litigation maximum strength false advertising Procter Gamble CVS Haleon Kenvue Perrigo 2024 2026
工具调用 · 历史记录,结果未知(3 种)
- search_processed_events · 结果未知
- stock_quote · 结果未知
- kb_search · 结果未知
原文全文
展开原文 · 2,665 字
A federal appeals court on Thursday revived portions of nationwide litigation in which consumers accused drugmakers such as Procter & Gamble (PG.N) and retailers such as CVS (CVS.N) of selling billions of dollars of over-the-counter decongestants that didn't work.
The litigation comprised about 100 lawsuits filed after a U.S. Food and Drug Administration advisory panel found in September 2023 that oral phenylephrine, an ingredient in such products as Vicks NyQuil Severe Cold & Flu and Advil Sinus Congestion & Pain, was no better than a placebo.
A three-judge panel of the 2nd U.S. Circuit Court of Appeals in Manhattan said the Federal Food, Drug and Cosmetic Act preempted most of the consumers' state law-based claims, saying the defendants followed FDA labeling requirements.
But the court revived claims over decongestants labeled "maximum strength," because various defendants added that phrase on their own. It also revived claims over brand-name drugs approved through the federal New Drug Application process, because the defendants could have updated labels to reflect the latest science.
"The limitations on consumer plaintiffs' state law remedies may appear unfair, particularly when the FDA's own agency review has confirmed that oral PE does not work as a decongestant and when studies have impugned oral PE's efficacy for 20 years," Circuit Judge Denny Chin wrote. "The fix, however, must flow not from litigation but from the FDA."
LITIGATION 'FAR FROM OVER'
Thursday's decision also said consumers lacked standing to pursue a civil racketeering claim accusing the defendants of defrauding the public and the FDA.
Jonathan Selbin, a lawyer for the consumers, said they were "obviously disappointed" with parts of the decision and reviewing their next steps.
"For over a decade these manufacturers made billions of dollars selling products with a decongestant that they long knew — in many cases based on their own studies — was entirely ineffective at decongesting," he said. "This case is far from over."
Procter & Gamble makes Vicks NyQuil Severe Cold & Flu, while Haleon (HLN.L) makes Advil Sinus Congestion & Pain. Some of the other defendants included Bayer (BAYGn.DE), GSK (GSK.L), Kenvue (KVUE.N), Costco (COST.O), Target (TGT.N), Walgreens and Walmart (WMT.O), as well as CVS.
Lawyers for those companies did not immediately respond to requests for comment.
The appeals court returned the litigation to U.S. District Judge Brian Cogan in Brooklyn, who dismissed it in October 2024.
In November 2024, the FDA proposed removing oral phenylephrine as an ingredient in over-the-counter oral cold medications.
The litigation comprised about 100 lawsuits filed after a U.S. Food and Drug Administration advisory panel found in September 2023 that oral phenylephrine, an ingredient in such products as Vicks NyQuil Severe Cold & Flu and Advil Sinus Congestion & Pain, was no better than a placebo.
A three-judge panel of the 2nd U.S. Circuit Court of Appeals in Manhattan said the Federal Food, Drug and Cosmetic Act preempted most of the consumers' state law-based claims, saying the defendants followed FDA labeling requirements.
But the court revived claims over decongestants labeled "maximum strength," because various defendants added that phrase on their own. It also revived claims over brand-name drugs approved through the federal New Drug Application process, because the defendants could have updated labels to reflect the latest science.
"The limitations on consumer plaintiffs' state law remedies may appear unfair, particularly when the FDA's own agency review has confirmed that oral PE does not work as a decongestant and when studies have impugned oral PE's efficacy for 20 years," Circuit Judge Denny Chin wrote. "The fix, however, must flow not from litigation but from the FDA."
LITIGATION 'FAR FROM OVER'
Thursday's decision also said consumers lacked standing to pursue a civil racketeering claim accusing the defendants of defrauding the public and the FDA.
Jonathan Selbin, a lawyer for the consumers, said they were "obviously disappointed" with parts of the decision and reviewing their next steps.
"For over a decade these manufacturers made billions of dollars selling products with a decongestant that they long knew — in many cases based on their own studies — was entirely ineffective at decongesting," he said. "This case is far from over."
Procter & Gamble makes Vicks NyQuil Severe Cold & Flu, while Haleon (HLN.L) makes Advil Sinus Congestion & Pain. Some of the other defendants included Bayer (BAYGn.DE), GSK (GSK.L), Kenvue (KVUE.N), Costco (COST.O), Target (TGT.N), Walgreens and Walmart (WMT.O), as well as CVS.
Lawyers for those companies did not immediately respond to requests for comment.
The appeals court returned the litigation to U.S. District Judge Brian Cogan in Brooklyn, who dismissed it in October 2024.
In November 2024, the FDA proposed removing oral phenylephrine as an ingredient in over-the-counter oral cold medications.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。